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Abstract
Background and Aims: Gastrointestinal stromal tumors 
(GISTs) are rare malignancies but the most common mesen-
chymal tumors of the digestive tract. Recent advances in di-
agnostic imaging and an increasing incidence will confront 
us more frequently with stromal tumors. This single center 
study aimed to characterize GIST patients in terms of tumor 
location, clinical presentation, metastasis formation, as well 
as associated secondary malignancies. Methods: In a retro-
spective study, 104 patients with a histologically confirmed 
diagnosis of GIST, collected between 1993 and 2011, were 
characterized for several clinical features. Results: The most 
common GIST location was the stomach (67.6%) followed by 
the small intestine (16.2%). Gastrointestinal bleeding (55.8%) 
and abdominal pain (38.5%) were the most frequently re-
ported symptoms whereas about one-third of patients re-
mained clinically asymptomatic (31.6%); 14.4% of patients 
had either synchronous or metachronous metastases and 
there was a significant prevalence also in the low risk group. 
The proportion of secondary malignant associated neo-
plasms was 31% in our GIST cohort, among which gastroin-
testinal, genitourinary tumors, and breast cancer were the 
most prevalent. Conclusion: There was a considerable risk 
for metastasis formation and the development of secondary 
neoplasias that should encourage discussion about the ap-
propriate surveillance strategy after surgery for GIST.
© 2018 S. Karger AG, Basel
Introduction
With only 0.1–3% of all gastrointestinal neoplasms, 
gastrointestinal stromal tumors (GISTs) are a rare tumor 
entity. Nonetheless they represent the most common 
mesenchymal tumors of the digestive tract and are even 
found in extraintestinal locations (eGIST) [1, 2]. Arising 
from the interstitial cells of Cajal or their precursors, they 
show a set of characteristic features including a spindle 
cell, epithelioid or, rarely, a pleomorphic morphology. 
A.A. and A.C. are both first authors.
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Mutations in the genes for cKIT (CD117; 85% of all GIST) 
and platelet-derived growth factor receptor alpha (5–7%) 
were ascribed a central role in the pathogenesis by perma-
nent tyrosine kinase activation [3–5].
The annual incidence of GISTs ranges from 0.7 to 2 per 
100,000 and increased during the last years [6, 7]. Data 
from the Surveillance, Epidemiology, and End Results 
registry from the U.S. National Cancer Institute found an 
age-adjusted yearly incidence of 6.8 per million [8, 9].
Several risk classifications systems exist for stratifica-
tion of stromal tumors such as those by Fletcher et al. [10], 
the modified National Institutes of Health (NIH) classifi-
cation by Joensuu et al. [11], or the TNM-classification 
[12]. The ESMO guidelines favor the use of a classifica-
tion by the Armed Forces Institute of Pathology (AFIP) 
[6] that considers tumor size, location, and their mitotic 
rate as prognostic factors [13]. Modified NIH criteria en-
compass a fourth factor, which is tumor rupture [14].
In early stages, stromal tumors often remain asymp-
tomatic and are detected accidentally. Clinical symptoms 
vary and include gastrointestinal bleeding (51%), a palpa-
ble mass (36%), and abdominal pain (33%) whereby the 
stomach is the most common site of disease manifestation 
followed by the small intestine [15]. Usually diagnosis is 
achieved using a combination of endoscopy, laparoscopy, 
and computed tomography [6]. Treatment options are 
manifold depending on the size and location of the tumor, 
localized or metastasized disease status, age, and comor-
bidities of the patient and include surgical and medical 
procedures. Standard treatment comprises surgical exci-
sion unless oncologic resection is feasible and no major 
comorbidity exists. In case of a high estimated risk for GIST 
recurrence after surgery, adjuvant therapy with tyrosine 
kinase inhibitors (imatinib) is initiated [16]. Mutational 
analysis is critical as some genotypes limit the success of 
adjuvant therapy such as in platelet-derived growth factor 
receptor alpha D842V-mutated GISTs. In locally advanced 
and metastasized stages, imatinib is the standard treatment 
and dose modification may be required according to the 
genotype of the KIT gene. In case of tumor progression or 
intolerance, sunitinib and regorafenib are considered as 
second- and third-line treatment options [6, 17, 18].
As known for other malignant tumors, GISTs harbor 
a risk of relapse and metastasis formation [19]. Secondary 
tumors, mainly gastrointestinal malignancies, have been 
reported in association with stromal tumors, which fur-
ther worsen prognosis [20, 21].
Here, we present data on GIST patients that were di-
agnosed in a single center in Western Pommerania, a ru-
ral region of Germany, in a time period from 1993 to 
2011. We focused on clinical symptoms and their pres-
ence depending on tumor location. Secondly, we investi-
gated the occurrence of metastases and the prevalence of 
associated secondary tumors.
Patients and Methods
Selection of Patients
After ethical approval from the local institutional review board 
committee, we collected clinicopathological and follow-up data 
of  patients with the diagnosis of a GIST at University Medicine 
 Greifswald in a retrospective monocentric analysis between 1993 and 
2011. Patients were identified in the hospital information system us-
ing the ICD-10 codes C15 to C18 and C48. and via cross-checking of 
histology reports of the Institute of Pathology. A total of 104 patients 
were identified with residence in Western Pomerania (urban district 
of Greifswald, Vorpommern-Greifswald, Vorpommern-Rügen, and 
Mecklenburg-Lake counties). The diagnosis of GIST was histologi-
cally confirmed for all patients and was done in all cases by the Insti-
tute of Pathology of University Medicine Greifswald. From 1993 to 
1998, diagnosis of GIST was established retrospectively because this 
tumor was defined as an independent entity in 1998 [22]. Tumors 
were immune-stained for CD117, CD34, and smooth muscle anti-
gen. Specimens from 1993 to 1998 were retrospectively stained with 
CD117 and CD34. The number of residents in Western Pomerania 
(the same catchment area) was obtained from the statistical office of 
Mecklenburg-Western Pomerania based on the census of 2013 [23]. 
The number of inhabitants was 727,270 on January 1, 2013. 
Acquisition of Clinical Data and Statistical Analysis
After identification of patients, they were contacted by mail and 
informed about the intention and type of study. A written informed 
consent was obtained from all still living individuals. In those pa-
tients who already died, consent was obtained by proxy and data 
fully anonymized. Patient data included gender, age at diagnosis of 
GIST, clinical symptoms, size, localization and genotype of the tu-
mor, diagnostic examinations performed, therapy, and follow-up 
data. Histological subtypes of GIST and proliferation index were as-
sessed, too. Risk of tumor recurrence was stratified according to the 
AFIP-Miettinen classification system, the Fletcher consensus crite-
ria, and the modified NIH classification by Joensuu, whenever pos-
sible. Results were reported as percentages, mean ± SD, and median 
and range, when applicable. A 2-tailed p value of < 0.05 was consid-
ered to be significant. Data were collected using Microsoft® Access 
2013 (Redmond, WA, USA) software and have been analyzed by the 
translational research platform tranSMART in version 16.2 [24].
Results
Characterization of the Cohort and Pathology 
of the Tumor
The study included 104 patients showing an almost 
equal distribution of female (48.1%) and male (51.9%) pa-
tients. Mean age of first diagnosis of GIST was 66.86 years 
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(SD 11.85 years) and median age was 70 years. We calcu-
lated the approximate annual incidence of GISTs between 
1999 and 2010 based on the population in Western-
Pomerania with a mean of 1.1 per 100,000 and a variance 
of 0.4–2.6 per 100,000. Mean follow-up for all patients was 
30.9 months and was carried out for up to 180 months.
The mean tumor size in our cohort was 4.96 cm (range 
from 0.2 to 20 cm). Histologically, more than 75% of all 
tumors showed a spindle cell configuration whereas epi-
thelioid cell and mixed type pattern were found more 
rarely (Table 1).
Localization of GISTs 
Data were available for almost all patients (n = 102). One 
patient had both gastric and an extraintestinal GIST (dia-
phragm). GISTs were widely distributed along the entire 
gastrointestinal tract. By far, the most frequent location 
was the stomach where around two-thirds of all tumors 
were found. It was found that 16.2% of all GISTs were lo-
cated in the small intestine whereas only 2.9% of the tumors 
were found in the colorectum. Esophageal location was 
seen in 4.8%. Extraintestinal manifestation was observed 
for 7 tumors corresponding to 6.7% of all GISTs (Table 2).
Risk Stratification
Based on tumor size, localization, and proliferation 
rate (mitotic index), tumor stage classification and risk 
assessment were performed. We used the classification 
systems of the AFIP [13], NIH [10], as well as the modi-
fied NIH criteria [11] and were able to classify 89 patients 
Table 1. Characterization of the study group
Quality Results
Age and gender
Patients with diagnosis of GIST 104
Age at diagnosis, years, mean ± SD (range) 66.86±11.85 (30–88)
Males, n (%) 54 (51.9)
Tumor size and histology 
Tumor diameter available 94
Tumor size, cm, mean ± SD (range) 4.96±3.85 (0.2–20)
Histology available 93
Spindle cell, n (%) 72 (77.4)
Epithelioid cell, n (%) 12 (12.9)
Mixed type, n (%) 9 (9.7)
Clinical symptoms
Data of clinical symptoms available 76 (73.1% of all 104 patients)
Clinical symptoms present, n (%) 52 (68.4)
Clinically asymptomatic, n (%) 24 (31.6)
Metastases
Patients with metastases 15
Synchronous metastases, n (%) 5 (33.3)
Metachronous metastases, n (%) 10 (66.6)
Mean time of recurrence, years 3.6
Secondary neoplasia, n (%)
Secondary neoplasia in addition to GIST 44 (42.3)
Malignant neoplasia 32 (72.7)
Benign neoplasia 14 (31.8)
Malignant and benign neoplasia 3 (6.8)
Table 2. Localization of GIST in the gastrointestinal tract and ex-
traintestinal location
Localization of GIST Number Percentage
Stomach 71 67.6
Small intestine 17 16.2
Colorectum 3 2.9
Esophagus 5 4.8
eGIST 7 6.7
No data available 2 1.9
Total 105* 100* Multiple locations found in 1 patient.
GIST, gastrointestinal stromal tumor; eGIST, extraintestinal 
eGIST.
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by NIH criteria and 87 by modified NIH and AFIP crite-
ria, respectively. When classifying according to the most 
widely used AFIP system, more than half of patients were 
grouped to a low (49.4%) or even very low (19.5%) tumor 
recurrence risk (Table 3). The percentage of patients with 
a very low recurrence risk was comparable in all 3 classi-
fication systems. Low recurrence risk was more frequent-
ly seen (49.4%) when applying the APIF criteria com-
pared to the modified NIH criteria (32.2%) or the initial 
consensus approach by Fletcher et al. [10] (33.7%). In 
contrast, only 6.9% of patients had an intermediate tumor 
recurrence risk according to the AFIP criteria which was 
remarkably higher (20.7 and 25.8%, respectively) after 
application of other classification systems. Numbers of 
patients having a high risk were quite comparable in all 3 
classification systems (Table 3).
Clinical Symptoms at First Diagnosis
Data regarding presence of clinical symptoms of GIST 
patients at hospital admission were available for 76 out of 
104 patients (73.1%). Among them 52 patients (68.4%) 
had symptoms, whereas the remainder was asymptom-
atic and diagnosis was established during routine exami-
nations or accidentally during a diagnostic workup due to 
other reasons. We observed a variety of clinical symp-
toms that were often unspecific and not directly indicat-
ing an underlying tumor disease. Gastrointestinal bleed-
ing was the most common reported clinical sign (55.8%), 
followed by abdominal pain (38.5%), weight loss (13.5%), 
nausea/vomiting (9.6%), heartburn (9.6%), and dizziness 
(7.7%; Table 4). 
In a next step, clinical symptoms were analyzed in re-
lation to tumor localization in order to clarify whether 
particular symptoms are associated with a specific tumor 
site. We only considered patients where both informa-
tion on GIST localization and clinical symptoms were 
available (online suppl. Table 1; for all online suppl. 
 material, see www.karger.com/doi/10.1159/000489556). 
Most data on symptoms were available for gastric GISTs 
since this tumor entity was the most common one. Gas-
trointestinal bleeding was most frequently reported by 
patients with GISTs of the stomach (64%), the small in-
testine (46.7%), and the colorectum (33.3%), although 
the absolute number of patients with colorectal GISTs 
was quite low. Regarding tumors of the stomach, abdom-
inal pain was reported by 28% of patients, whereas an-
other 28% of patients did not report any clinical symp-
toms. Abdominal pain was also associated with tumors 
of other sites, as in 25% for esophageal, 20% for small 
intestinal, and 50% for extraintestinal GIST location but 
tumor prevalence was much lower compared to gastric 
location.
Metastasis Formation of GISTs
Patients were further analyzed for occurrence of me-
tastases; 15 out of 104 patients were diagnosed with me-
tastases, of which 5 (33.3%) had synchronous and 10 
(66.6%) metachronous metastases. Patients with local tu-
mor recurrence after surgery (2 individuals) were also 
included to the group with metachronous metastases. In 
all patients with synchronous and metachronous metas-
Table 3. Recurrence risk according to the classifications of Fletcher et al. [10], Miettinen et al. [13], and Joensuu 
et al. [11]
Recurrence risk NIH (Fletcher et al. [10],
2002), n (%)
AFIP (Miettinen et al. [13],
2006), n (%)
Modified NIH (Joensuu
et al. [11], 2008), n (%)
Very low 14 (15.7) 17 (19.5) 17 (19.5)
Low 30 (33.7) 43 (49.4) 28 (32.2)
Intermediate 23 (25.8) 6 (6.9) 18 (20.7)
High 22 (24.7) 21 (24.1) 24 (27.6)
Total 89 (100) 87 (100) 87 (100)
Table 4. Most frequently reported clinical symptoms of patients 
with GIST at first diagnosis (multicode allowed)
Symptom Number of patients, n (%)
Gastrointestinal bleeding 29 (55.8)
Abdominal pain 20 (38.5)
Weight loss 7 (13.5)
Weakness/dizziness 7 (13.5)
Heartburn 5 (9.6)
Nausea/vomiting 5 (9.6)
Loss of appetite 2 (3.8)
Dyspnea 2 (3.8)
Ileus 2 (3.8)
Feeling of fullness 2 (3.8)
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tases, origin from a GIST was confirmed by histology. 
The mean time between initial GIST diagnosis and ap-
pearance of metastases was 3.6 years (ranging from 1 to 
15 years). The most frequent location was the liver (10 of 
15 patients, 66.7%), rarer sites included the peritoneum 
(4 of 15, 26.7%), bones (2 of 15, 13.3%), lymph nodes (2 
of 15, 13.3%), and pancreas and the colon (1 of 15, 6.7%). 
To determine independent variables for recurrence-
free survival, Kaplan-Meier analyses were calculated us-
ing the categories tumor location (stomach, esophagus, 
small intestine, eGIST), size (< 5, 5.1–10 and 10.1–15 cm), 
and mitotic index (0–5, 6–10, > 10 mitoses/high power 
field). Small tumors (< 5 cm) and those with a low mitot-
ic index (< 5/high power field) were associated with a low-
er disease-free survival. No clear association was found 
for tumor location acknowledging a small patient size as 
a limiting factor (online suppl. Fig. 1). 
Next, we compared patients with synchronous or 
metachronous metastases by using the commonly used 
risk classifications in order to determine the accuracy of 
predicting metastatic disease. Again we used the NIH, 
modified NIH, and AFIP criteria that were available for 
15 and 14 patients, respectively (Table 5). As expected, 
the majority of patients with metastases belonged to the 
high risk group (71.4 and 73.3%), irrespective of the clas-
sification system used. Only 1 patient belonged to the 
group with an intermediate risk when using the criteria 
by Fletcher (6.6%) and Joensuu (7.1%). Around 20% be-
longed to the low and very low risk group and this num-
ber was even higher when applying the criteria of Miet-
tinen (28.5%). In consideration of all patients (Table 3), a 
tumor progression was noted for 41.6–50% of the high 
risk group, 0–5.6% of the intermediate group, 6.7–7.1% 
of the low risk group, and 5.9–7.1% of the very low risk 
group patients, depending on the risk classification that 
was applied.
Secondary Malignant Lesions in GIST Patients
Various malignancies are known to be associated with 
an increased rate of malignant tumors at other, unrelated 
sites. Secondary neoplasias may precede or succeed the 
index admission for GIST or are detected simultaneous-
ly. We studied how many GIST patients suffered from a 
secondary neoplasm and which kind of tumor they had 
developed during the same observation period; 44 pa-
tients (42.3%) were diagnosed with a secondary tumor of 
any kind (benign, semi-malignant, or malignant) in ad-
dition to the GIST. In 32 patients (30.8%), 38 malignant 
tumors were found. Among them, 9 tumors were known 
for at least 1 year before diagnosis of GIST, while 18 tu-
mors were diagnosed within the time period of ±1 year 
of index admission for GIST and 9 malignant tumors 
were diagnosed at least 1 year after the diagnosis of a 
GIST. In 2 cases, the exact time of diagnosis of the sec-
ondary neoplasm could not be retrieved retrospectively. 
Among them, 26 individuals had 1 additional malignan-
cy and 6 patients 2 more malignant tumors. Moreover, 
15 benign tumors were detected in 14 patients (13.5%) 
and 3 semi-malignant tumors (basal cell carcinoma) were 
found in 3 patients (2.9%). Combinations of either be-
nign, semi-malignant, or malignant tumors existed in 5 
patients.
The number and site of malignant neoplasias are 
shown in Table 6. Carcinomas of the gastrointestinal 
tract were observed most frequently (52.6%) followed 
by tumors of the urogenital tract (21.1%) and the mam-
mary gland (18.4%). Regarding organ involvement, 
 secondary malignancies were most often seen in the co-
lon (26.3%) and the stomach and the prostate (15.8%). 
Rarer entities were hematologic neoplasias (5.3%) and 
a peripheral nerve sheath tumor (2.6%), a type of 
 sarcoma originating from the surrounding tissue of 
nerves.
Table 5. Presence of GIST metastases in relation to risk classifications of Fletcher et al. [10], Miettinen et al. [13], 
and Joensuu et al. [11]
Recurrence risk Number of patients, n (%)
high risk intermediate risk low risk very low risk all
NIH
(Fletcher et al. [10], 2002)
11 (73.3) 1 (6.7) 2 (13.3) 1 (6.7) 15 (100)
AFIP
(Miettinen et al. [13], 2006)
10 (71.4) 0 (0) 3 (21.4) 1 (7.1) 14 (100)
Modified NIH
(Joensuu et al. [11], 2008)
10 (71.4) 1 (7.1) 2 (14.3) 1 (7.1) 14 (100)
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Discussion
GISTs are common mesenchymal neoplasias of the 
gastrointestinal tract. Within the last decades, much 
progress has been made not only in understanding the 
molecular biology of these tumors but also regarding di-
agnostic and therapeutic options [25].
Here we characterized GIST patients from a tertiary care 
hospital in north-eastern Germany diagnosed between 
1993 and 2011. On the one hand, we focused on clinical 
symptoms of these patients in relation to the tumor localiza-
tion, and on the other hand, we studied metastasis forma-
tion and the association with secondary malignancies.
In our cohort, the calculated annual incidence of GISTs 
was between 0.4 and 2.6 per 100,000 and thus in line with 
reported data from other groups, especially from north-
western Europe (The Netherlands, Sweden, Iceland) 
where it ranged from 0.7 to 2.0 per 100,000 [7, 26, 27]. 
Since our hospital is the only tertiary referral center 
in  Western Pomerania, a rural area in north-eastern 
 Germany with a population of around 700,000 inhabit-
ants [23], it is a well suited area to make near population-
based assessments, because nearly all patients are referred 
to this hospital. Secondly, the study population was well 
defined and histology was available for patients from the 
same team of pathologists. In our cohort, the mean age at 
first diagnosis of GIST was slightly higher (66.86 years) 
compared to other series reporting a range between 57.8 
and 65 years [28–30]. This may be due to a slightly older 
population in north-eastern Germany compared to the 
rest of the country being more than 3 years above the 
mean [31–34]. Another reason for the later age at diagno-
sis may be a more limited access to specialist care in this 
rural area.
As outlined by the AFIP tumor size, mitotic index and 
location are prognostic factors for this tumor entity. In 
our study, the mean tumor size was 4.96 cm and thus 
quite comparable to another population-based study on 
GISTs from Europe [27]. Around two-thirds (67.6%) 
were located in the stomach, consistent to other groups 
who indicated gastric GISTs being the most frequent 
stromal tumor in 40–60% of cases. Tumor manifestation 
in the small intestine was seen in 16.2%, compared to 
studies that found jejunal or ileal stromal tumors in 20–
50% of patients [15, 19, 35]. In contrast to the small intes-
tine, a colorectal manifestation is rarely observed having 
an incidence of 4.0–6.4% and thus slightly higher than in 
our cohort (2.9%) [15, 19, 21, 35]. Esophageal location 
was comparably very low to other studies (mostly < 5%), 
the same was true for extraintestinal GISTs. Data for ex-
traintestinal GISTs were rather scarce. In a large mono-
centric study of 200 patients with GIST, an extraintestinal 
location was seen in 8% whereby they also included 
esophageal tumors in that entity [29].
Table 6. Occurrence and site of secondary malignant neoplasms in our cohort and comparison to literature
Our cohort number
of tumors, n (%)
Pandurengan et al. [1], 
2010, n (%)
Agaimy et al. [41], 
2006, n (%)
Carcinoma of the urogenital tract All 8 (21.1) 62 (33) 111 (23)
Prostate cancer 6 (15.8) 28 (15) 43 (9)
Kidney cancer 1 (2.6) 12 (6.5) 27 (6)
Urothelial cancer 1 (2.6) 7 (3.8) 10 (2)
Carcinoma of the gastrointestinal tract All 20 (52.6) 48 (26) 228 (47)
Colorectal cancer 10 (26.3) 18 (9.7) 109 (22)
Pancreatic cancer 3 (7.9) 5 (2.7) 11 (2)
Gastric cancer 6 (15.8) 5 (2.7) 95 (19)
Gallbladder cancer 1 (2.6) 1 (0.5) 4 (1)
Breast cancer 7 (18.4) 15 (8) 34 (7)
Hematologic neoplasia Lymphoma/
leukemia
2 (5.3) 12 (6.5) 36 (7)
Malignant peripheral nerve sheath tumor 1 (2.6) NA NA
Total number of additional malignancies 38 (100) 186 (100) 518 (100)
NA, not available.
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A considerable number of our patients (around 30%) 
remained clinically asymptomatic. In these patients, diag-
nosis was often established either by radiologic, ultra-
sound, or endoscopic examinations done for reasons other 
than a suspected tumor, during an operation, or in surgi-
cal specimens after bariatric surgery. The frequency of as-
ymptomatic GIST patients is in line with other studies that 
reported an incidence of 10–30% [35]. Establishing the di-
agnosis of GIST is still challenging as these tumors do not 
have a specific clinical manifestation. Moreover, symp-
toms depend on tumor size and can be observed in other 
gastrointestinal disorders as well [36]. In addition, some 
patients present with more than 1 clinical sign. In our co-
hort, common symptoms were gastrointestinal bleeding 
including either hematemesis, hematochezia, melena or a 
positive stool blood test (55.8%), abdominal pain (38.5%), 
weight loss, or a general feeling of weakness and dizziness 
(each 13.5%). These observations were in line with other 
series that found comparable results [15, 21, 36, 37]. 
We were further interested in whether specific clinical 
symptoms of GIST patients may predict tumor location. 
For gastric GISTs, the largest subgroup, gastrointestinal 
bleeding was by far the most common reported symptom 
(64%) and more frequently observed than for other GIST 
locations. Abdominal pain was less often seen when com-
pared to all GISTs together (28 vs. 38.5%). The absence of 
clinical symptoms was often noted when tumor site was in 
the esophagus, small, or large intestine. However, numbers 
of patients in the latter subgroups were rather small so that 
these results have to be interpreted with caution. Our re-
sults confirm observations from Caterino et al. [21] who 
found that bleeding in the digestive tract was more frequent 
in gastric GISTs than for other localizations. Abdominal 
pain was observed almost as often as bleeding which differs 
to our results [21]. However, their patient cohort was small-
er. In addition, as in our study, the authors were also con-
fronted with a low case load for extra-gastric stromal tu-
mors making representative statistics more difficult. 
An accurate prediction of the biological behavior of 
GISTs is challenging. The majority of our tumors were clas-
sified with a low or very low recurrence risk independent 
of the type of classification that was used. Around one-
quarter of patients belonged to the high risk group (24.1–
27.6%). Regarding metastasis formation only 15 out of 104 
(14.4%) patients were diagnosed with metastatic disease. 
Among them two-thirds had metachronous and one-third 
synchronous metastases. We compared the presence of 
metastases to the most commonly used risk classification 
systems in order to see accuracy of prediction. As expected, 
more than 70% of patients with metastases belonged to the 
high risk group. Only a minority of patients were classified 
as intermediate or very low risk. In contrast to our expecta-
tions, our data show that even 13.3–21.4% of metastasized 
patients belonged to the low risk group.
A recently published large single center study (n = 497) 
investigating tumor recurrence in GIST patients found a 
slightly higher risk of overall tumor recurrence or metasta-
sis formation which was 19.7% [38]. However, hardly any 
tumor relapse was observed in the low risk and very low risk 
groups. There may be various reasons explaining this dis-
crepancy. One is that our study contained a higher propor-
tion of low and very low risk GIST cases. Secondly, there 
may be differences regarding the time of tumor diagnosis, 
operation, and adjuvant chemotherapy between the cen-
ters that may influence recurrence rates. Further studies 
will be necessary to elucidate this question. In addition, the 
absolute number of patients with metastasis formation or 
tumor recurrence was low in the low risk categories making 
a universal conclusion difficult. In a large meta-analysis of 
population-based studies including 2,560 GIST patients 
and a validation series of 920 patients, Joensuu et al. [39] 
identified the modified NIH classification as most suitable 
criteria for identification of high risk groups among the 
commonly used classification systems. Secondly, they de-
veloped a new method for estimation of GIST recurrence 
by including tumor localization and rupture status and re-
specting the non-linear effect of mitosis and tumor size on 
recurrence-free survival. Our data showed that NIH crite-
ria predicted tumor recurrence (73.3%) slightly better than 
modified NIH criteria and AFIP criteria (71.4%); however, 
only 15 of our patients had metastases.
Besides metastasis formation, the occurrence of sec-
ondary neoplasms worsens the prognosis of GIST pa-
tients. There is evidence that coexisting secondary neo-
plasms appear more often in GIST patients than in the 
general population [1, 40] and an association of GISTs 
with both solid and hematologic tumors were reported. 
The overall frequency of secondary tumors varies from 
4.5 to 33% with a mean of 13% [1, 41]. According to 
Agaimy et al. [41], gastric cancer (47%), prostate cancer 
(9%), breast cancer or lymphoma, as well as leukemia 
(both 7%) were reported in association with GISTs, fol-
lowed by kidney (6%) and lung cancer (5%) as well as tu-
mors of the female reproductive tract (5%). In a large sin-
gle center study of 783 patients, 20% were diagnosed with 
at least 1 additional primary [1] and the majority of tu-
mors were of genitourinary (33%) or gastrointestinal 
(26%) origin. To a lesser extent, breast cancer (8%) and 
hematologic neoplasias (6.5%) were seen. In our series, 
more than 40% of GIST patients were diagnosed with an 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
ita
et
sb
ib
lio
th
ek
 E
rla
ng
en
-N
ue
rn
be
rg
   
   
   
   
 
13
1.
18
8.
6.
20
0 
- 9
/5
/2
01
9 
10
:0
8:
19
 A
M
Aghdassi/Christoph/Dombrowski/
Döring/Barth/Christoph/Lerch/Simon
Dig Dis8
DOI: 10.1159/000489556
additional tumor, irrespective of dignity. A malignant 
secondary neoplasia was observed in 30.8% and thus be-
ing in the upper range of reported prevalences. Three pa-
tients (2.9%) had diagnosis of both a benign and a malig-
nant neoplasia. Potential reasons for our comparatively 
high number of secondary neoplasms are a longer follow-
up time in our study that was up to 15 years and a much 
higher mean age of our study population which was 
around 67 years at the first diagnosis of GIST, and thus 
more than 10 years older than in the aforementioned 
study [1]. In addition, our patient group was exclusively 
of Caucasian ancestry. Our data support the high inci-
dence of secondary GI neoplasms in GIST patients, espe-
cially colorectal, gastric, and pancreatic cancer.
There are limitations of our study. The retrospective 
setting caused missing data that we had to correct for 
when analyzing histopathology and clinical symptoms. 
Information on clinical signs was unavailable for about 
25% of patients. Therefore, a subgroup analysis of symp-
toms depending on GIST localization is challenging due 
to small numbers. In addition, reporting of patient’s com-
plaints in a retrospective analysis has limitations as they 
have to be retrieved from the patient file which might be 
incomplete. Reporting of symptoms in a prospective de-
sign would be a superior approach. Secondly, a compre-
hensive characterization of GISTs needs to include an 
analysis of genetic changes that are likely to further affect 
survival [42]. Larger, preferably multicenter studies will 
be necessary to determine symptoms depending on tumor 
location, especially for extra-gastric tumor sites. More-
over, the small number of patients limits the calculation 
of probability of disease recurrence after surgery, since 
follow-up data were available for only 39 patients and ex-
act time of death was known for 12 patients. Metachro-
nous metastases were detected in only 10 patients. Larger 
studies with pooled data will be an ideal approach for es-
timation of GIST recurrence as published previously [39]. 
In summary, we presented a clinical characterization of 
a single center cohort of GIST patients. Clinical symptoms 
correlated with tumor location, most remarkably for gas-
tric location. There was a considerable risk for tumor re-
currence, metastasis formation, and the occurrence of sec-
ondary malignant tumors. A comparably higher risk for 
metastases was detected especially in low risk patients. 
These observations have clinical implications. First, even 
patients in lower risk groups may benefit from follow-up 
examinations, although it remains unclear whether this is 
cost-effective, and secondly, GIST patients with their in-
creased risk of developing secondary tumors at unrelated 
sites may benefit from surveillance and screening pro-
grams for colorectal, breast, and prostate cancer. 
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